<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1d3" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">68843</article-id><article-id pub-id-type="doi">10.7554/eLife.68843</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Short Report</subject></subj-group><subj-group subj-group-type="heading"><subject>Cell Biology</subject></subj-group><subj-group subj-group-type="heading"><subject>Stem Cells and Regenerative Medicine</subject></subj-group></article-categories><title-group><article-title>The pro-regenerative effects of HyperIL6 in drug induced liver injury are unexpectedly due to competitive inhibition of IL11 signaling</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-233161"><name><surname>Dong</surname><given-names>Jinrui</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-233162"><name><surname>Viswanathan</surname><given-names>Sivakumar</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-249213"><name><surname>Adami</surname><given-names>Eleonora</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-233164"><name><surname>Schafer</surname><given-names>Sebastian</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-233166"><name><surname>Kuthubudeen</surname><given-names>Fathima F</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-232168"><name><surname>Widjaja</surname><given-names>Anissa A</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-9404-7608</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="par-7"/><xref ref-type="fn" rid="conf3"/></contrib><contrib contrib-type="author" corresp="yes" id="author-209733"><name><surname>Cook</surname><given-names>Stuart A</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-6628-194X</contrib-id><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="corresp" rid="cor1">*</xref><xref ref-type="other" rid="par-1"/><xref ref-type="other" rid="par-2"/><xref ref-type="other" rid="par-3"/><xref ref-type="other" rid="par-4"/><xref ref-type="other" rid="par-5"/><xref ref-type="other" rid="par-6"/><xref ref-type="fn" rid="conf4"/></contrib><aff id="aff1"><institution content-type="dept">Cardiovascular and Metabolic Disorders</institution>, <institution>Duke-National University of Singapore Medical School</institution>, <addr-line><named-content content-type="city">Singapore</named-content></addr-line>, <country>Singapore</country></aff><aff id="aff2"><institution content-type="dept">CVMD</institution>, <institution>National Heart Research Institute of Singapore</institution>, <addr-line><named-content content-type="city">Singapore</named-content></addr-line>, <country>Singapore</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor" id="author-30545"><name><surname>Ardehali</surname><given-names>Hossein</given-names></name><role>Reviewing editor</role><aff><institution>Northwestern University</institution>, <country>United States</country></aff></contrib></contrib-group><author-notes><corresp id="cor1"><label>*</label>For correspondence: <email>stuart.cook@duke-nus.edu.sg</email> (SC);</corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>26</day><month>08</month><year>2021</year></pub-date><volume>10</volume><elocation-id>e68843</elocation-id><history><date date-type="received"><day>27</day><month>03</month><year>2021</year></date><date date-type="accepted"><day>24</day><month>08</month><year>2021</year></date></history><permissions><copyright-statement>Â© 2021, Dong et al</copyright-statement><copyright-year>2021</copyright-year><copyright-holder>Dong et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link> permitting unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-68843-v1.pdf"/><abstract><p>It is generally accepted that IL6-mediated STAT3 signaling in hepatocytes, mediated via glycoprotein 130 (gp130; IL6ST), is beneficial and that the synthetic IL6:IL6ST fusion protein (HyperIL6) promotes liver regeneration. Recently, autocrine IL11 activity that also acts via IL6ST but uses ERK rather than STAT3 to signal, was found to be hepatotoxic. Here we examined whether the beneficial effects of HyperIL6 could reflect unappreciated competitive inhibition of IL11-dependent IL6ST signaling. In human and mouse hepatocytes, HyperIL6 reduced N-acetyl-p-aminophenol (APAP)-induced cell death independent of STAT3 activation and instead, dose-dependently, inhibited IL11-related signaling and toxicities. In mice, expression of HyperIl6 reduced ERK activation and promoted STAT3-independent hepatic regeneration (PCNA, Cyclin D1, Ki67) following administration of either IL11 or APAP. Inhibition of putative intrinsic IL6 trans-signaling had no effect on liver regeneration in mice. Following APAP, mice deleted for <italic>Il11</italic> exhibited spontaneous liver repair but HyperIl6, despite robustly activating STAT3, had no effect on liver regeneration in this strain. These data show that synthetic IL6ST binding proteins such as HyperIL6 can have unexpected, on-target effects and suggest IL11, not IL6, as important for liver regeneration.</p></abstract><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Mouse</kwd></kwd-group><funding-group><award-group id="par-1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001349</institution-id><institution>National Medical Research Council</institution></institution-wrap></funding-source><award-id>NMRC/STaR/0029/2017</award-id><principal-award-recipient><name><surname>Cook</surname><given-names>Stuart A</given-names></name></principal-award-recipient></award-group><award-group id="par-2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001349</institution-id><institution>National Medical Research Council</institution></institution-wrap></funding-source><award-id>NMRC Centre Grant to the NHCS</award-id><principal-award-recipient><name><surname>Cook</surname><given-names>Stuart A</given-names></name></principal-award-recipient></award-group><award-group id="par-3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001349</institution-id><institution>National Medical Research Council</institution></institution-wrap></funding-source><award-id>MOH&amp;#x2010;CIRG18nov&amp;#x2010;0002</award-id><principal-award-recipient><name><surname>Cook</surname><given-names>Stuart A</given-names></name></principal-award-recipient></award-group><award-group id="par-4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000265</institution-id><institution>Medical Research Council</institution></institution-wrap></funding-source><award-id>MRC-LMS</award-id><principal-award-recipient><name><surname>Cook</surname><given-names>Stuart A</given-names></name></principal-award-recipient></award-group><award-group id="par-5"><funding-source><institution-wrap><institution>Goh Foundation</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Cook</surname><given-names>Stuart A</given-names></name></principal-award-recipient></award-group><award-group id="par-6"><funding-source><institution-wrap><institution>Tanoto Foundation</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Cook</surname><given-names>Stuart A</given-names></name></principal-award-recipient></award-group><award-group id="par-7"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001349</institution-id><institution>National Medical Research Council</institution></institution-wrap></funding-source><award-id>NMRC/OFYIRG/0053/2017</award-id><principal-award-recipient><name><surname>Widjaja</surname><given-names>Anissa A</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group></article-meta></front><back><sec id="s1" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interest</title><fn fn-type="conflict" id="conf2"><p>Sebastian Schafer, is a co-inventor of the patent applications: WO/2017/103108 (Treatment of Fibrosis), WO/2018/109174 (IL11 Antibodies), WO/2018/109170 (IL11RA Antibodies), and US 2020/0262910 (Treatment of Hepatotoxicity). Is a co-founder and shareholder of Enleofen Bio PTE LTD..</p></fn><fn fn-type="conflict" id="conf3"><p>Anissa A Widjaja, A.A.W is a co-inventor of the patent application: US 2020/0262910 (Treatment of Hepatotoxicity)..</p></fn><fn fn-type="conflict" id="conf4"><p>Stuart A Cook, S.A.C. is a co-inventor of the patent applications: WO/2017/103108 (TREATMENT OF FIBROSIS), WO/2018/109174 (IL11 ANTIBODIES), WO/2018/109170 (IL11RA ANTIBODIES), and US 2020/0262910 (Treatment of Hepatotoxicity). S.A.C. is a co-founder and shareholder of Enleofen Bio PTE LTD..</p></fn><fn fn-type="conflict" id="conf1"><p>The other authors declare that no competing interests exist.</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Animal experimentation: Animal studies were carried out in compliance with the recommendations in the Guidelines on the Care and Use of Animals for Scientific Purposes of the National Advisory Committee for Laboratory Animal Research (NACLAR). All experimental procedures were approved (SHS/2014/0925 and SHS/2019/1482) and conducted in accordance with the SingHealth Institutional Animal Care and Use Committee.</p></fn></fn-group></sec><sec id="s2" sec-type="supplementary-material"><title>Additional Files</title><sec id="s3" sec-type="data-availability"><title>Data availability</title><p>All data generated or analysed during this study are included in the manuscript and supporting files. Source data are provided with this paper.</p></sec><supplementary-material><ext-link xlink:href="elife-68843-supp-v1.zip">Download zip</ext-link><p>Any figures and tables for this article are included in the PDF. The zip folder contains additional supplemental files.</p></supplementary-material></sec></back></article>